FilingReader Intelligence
CSPC Innovation reports revenue drop, focus shifts to innovation
March 27, 2025 at 08:59 PM UTC•By FilingReader AI
CSPC Innovation Pharmaceutical (SZSE:300765) reported a 21.98% drop in revenue to RMB 1.98 billion for 2024, alongside a significant 87.63% plunge in net profit, according to its annual report. The company attributes the downturn to pricing pressures in its functional food and ingredient sectors.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
Primary Source Document
Supplementary Source Documents
2024 Annual ReportMarch 20, 2025 at 01:12 PM UTC
Announcement on the 2024 Profit Distribution PlanMarch 20, 2025 at 01:12 PM UTC
SDIC Securities Co., Ltd.'s review opinion on the extension of some fundraising projects of CSPC Pharmaceutical Innovations Pharmaceutical Co., Ltd.March 20, 2025 at 01:12 PM UTC
Announcement on the proposed expansion of business scope, revision of the Articles of Association and handling of industrial and commercial change registrationMarch 20, 2025 at 01:12 PM UTC
Announcement on the acceptance of financial assistance and related-party transactions by the holding subsidiaryMarch 20, 2025 at 01:12 PM UTC
Announcement on the Re-appointment of Accounting FirmsMarch 20, 2025 at 01:12 PM UTC
Announcement on the use of part of idle raised funds and own funds for cash managementMarch 20, 2025 at 01:12 PM UTC
Announcement on the extension of some fundraising projectsMarch 20, 2025 at 01:12 PM UTC
2024 Annual Report Disclosure Indicative AnnouncementMarch 20, 2025 at 01:12 PM UTC
2024 Annual Report SummaryMarch 20, 2025 at 01:12 PM UTC
SZSE:300765•Shenzhen Stock Exchange
News Alerts
Get instant email alerts when CSPC Innovation Pharmaceutical publishes news
Free account required • Unsubscribe anytime